Omeros Net Profit Margin 2009-2019 | OMER

Omeros net profit margin from 2009 to 2019. Net profit margin can be defined as net Income as a portion of total sales revenue.
Omeros Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2019-12-31 $0.11B $-0.08B -74.11%
2019-09-30 $0.10B $-0.08B -77.23%
2019-06-30 $0.08B $-0.10B -132.89%
2019-03-31 $0.05B $-0.12B -237.25%
2018-12-31 $0.03B $-0.13B -409.68%
2018-09-30 $0.02B $-0.12B -521.74%
2018-06-30 $0.04B $-0.09B -220.00%
2018-03-31 $0.06B $-0.07B -123.64%
2017-12-31 $0.07B $-0.05B -81.54%
2017-09-30 $0.06B $-0.06B -87.50%
2017-06-30 $0.05B $-0.06B -118.87%
2017-03-31 $0.05B $-0.06B -134.78%
2016-12-31 $0.04B $-0.07B -165.85%
2016-09-30 $0.04B $-0.07B -194.29%
2016-06-30 $0.03B $-0.07B -274.07%
2016-03-31 $0.02B $-0.08B -390.00%
2015-12-31 $0.01B $-0.08B -584.62%
2015-09-30 $0.01B $-0.08B -1283.33%
2015-06-30 $0.00B $-0.08B -2500.00%
2015-03-31 $0.00B $-0.08B inf%
2014-12-31 $0.00B $-0.07B inf%
2014-09-30 $0.00B $-0.06B inf%
2014-06-30 $0.00B $-0.05B inf%
2014-03-31 $0.00B $-0.05B inf%
2013-12-31 $0.00B $-0.04B -4000.00%
2013-09-30 $0.00B $-0.05B -1533.33%
2013-06-30 $0.00B $-0.05B -1125.00%
2013-03-31 $0.01B $-0.04B -666.67%
2012-12-31 $0.01B $-0.04B -650.00%
2012-09-30 $0.01B $-0.04B -820.00%
2012-06-30 $0.01B $-0.04B -700.00%
2012-03-31 $0.00B $-0.03B -775.00%
2011-12-31 $0.00B $-0.03B -725.00%
2011-09-30 $0.00B $-0.03B -650.00%
2011-06-30 $0.00B $-0.03B -900.00%
2011-03-31 $0.00B $-0.03B -1500.00%
2010-12-31 $0.00B $-0.03B -3000.00%
2010-09-30 $0.00B $-0.03B inf%
2010-06-30 $0.00B $-0.03B inf%
2010-03-31 $0.00B $-0.02B inf%
2009-12-31 $0.00B $-0.02B inf%
2009-06-30 $0.00B $-0.02B -1800.00%
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.663B $0.112B
Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $140.105B 24.52
Medtronic (MDT) Ireland $115.616B 15.54
Stryker (SYK) United States $55.501B 17.93
Boston Scientific (BSX) United States $43.519B 19.60
Baxter (BAX) United States $41.301B 0.00
Coloplast (CLPBY) Denmark $32.381B 49.97
Lonza Group Ag (LZAGY) Switzerland $30.517B 0.00
Terumo (TRUMY) Japan $24.814B 0.00
EssilorLuxottica Societe Anonyme (ESLOY) France $23.088B 0.00
ResMed (RMD) United States $22.122B 38.44
Zimmer Biomet Holdings (ZBH) United States $18.991B 11.69
Smith & Nephew SNATS (SNN) United Kingdom $14.868B 0.00
Sunny Optical Technology (SNPTF) China $14.665B 0.00
Bio-Rad Laboratories (BIO) United States $10.946B 51.16
Insulet (PODD) United States $10.367B 634.31
William Demant Holdings (WILYY) Denmark $7.898B 0.00
Hill-Rom Holdings (HRC) United States $7.034B 20.23
DiaSorin S.p.A (DSRLF) Italy $6.994B 0.00
GN STORE NORD (GNNDY) Denmark $6.057B 0.00
Perrigo (PRGO) Ireland $6.039B 11.01
Shandong Weigao Medical Polymer (SHWGF) China $5.020B 0.00
Haemonetics (HAE) United States $4.949B 30.46
Canopy Growth (CGC) Canada $4.629B 0.00
ICU Medical (ICUI) United States $4.256B 27.80
Quidel (QDEL) United States $3.979B 34.93
Neogen (NEOG) United States $3.373B 57.14
Agios Pharmaceuticals (AGIO) United States $2.569B 0.00
GW Pharmaceuticals (GWPH) United Kingdom $2.529B 0.00
Hutchison China MediTech (HCM) Hong Kong, SAR China $2.354B 0.00
NuVasive (NUVA) United States $2.269B 17.54
Envista Holdings (NVST) United States $2.062B 0.00
National Vision Holdings (EYE) United States $1.337B 22.53
AtriCure (ATRC) United States $1.273B 0.00
Cardiovascular Systems (CSII) United States $1.210B 0.00
Aurora Cannabis (ACB) Canada $0.986B 0.00
TG Therapeutics (TGTX) United States $0.979B 0.00
Phibro Animal Health (PAHC) United States $0.961B 19.01
NanoString Technologies (NSTG) United States $0.862B 0.00
VAREX IMAGING (VREX) United States $0.798B 16.58
DFB Healthcare Acquisitions (AHCO) United States $0.761B 0.00
Aphria (APHA) $0.754B 0.00
Cerus (CERS) United States $0.741B 0.00
OraSure Technologies (OSUR) United States $0.639B 79.31
InMode (INMD) Israel $0.619B 0.00
Eagle Pharmaceuticals (EGRX) United States $0.595B 35.39
PetIQ (PETQ) United States $0.582B 15.83
Quanterix (QTRX) United States $0.547B 0.00
LeMaitre Vascular (LMAT) United States $0.462B 26.00
Surmodics (SRDX) United States $0.432B 49.69
Owens & Minor (OMI) United States $0.427B 11.69
Lantheus Holdings (LNTH) United States $0.411B 9.23
Vapotherm (VAPO) United States $0.381B 0.00
Meridian Bioscience (VIVO) United States $0.363B 14.60
Zynex (ZYXI) United States $0.327B 35.61
Repro-Med Systems (KRMD) United States $0.298B 188.00
Utah Medical Products (UTMD) United States $0.292B 20.87
Organigram Holdings (OGI) Canada $0.280B 0.00
MacroGenics (MGNX) United States $0.257B 0.00
Cytosorbents (CTSO) United States $0.236B 0.00
BioLife Solutions (BLFS) United States $0.201B 123.00
Female Health (VERU) United States $0.196B 0.00
HEXO (HEXO) $0.192B 0.00
Viemed Healthcare (VMD) United States $0.164B 18.52
Exagen (XGN) United States $0.162B 0.00
United Health Products (UEEC) United States $0.132B 0.00
Evolus (EOLS) United States $0.130B 0.00
Rockwell Medical (RMTI) United States $0.124B 0.00
Bovie Medical (APYX) United States $0.122B 0.00
Chembio Diagnostics (CEMI) United States $0.121B 0.00
Neptune Wellness Solutions (NEPT) Canada $0.110B 0.00
Liberty Health Sciences (LHSIF) Canada $0.105B 0.00
Fonar (FONR) United States $0.093B 6.78
Chimerix (CMRX) United States $0.082B 0.00
Brainsway (BWAY) Israel $0.080B 0.00
MTech Acquisition (KERN) United States $0.069B 0.00
Green Organic Dutchman Holdings (TGODF) Canada $0.062B 0.00
United-Guardian (UG) United States $0.061B 12.69
Nephros (NEPH) United States $0.058B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.053B 0.00
Surface Oncology (SURF) United States $0.047B 0.00
GUARDION HEALTH (GHSI) United States $0.037B 0.00
ImmuCell (ICCC) United States $0.030B 0.00
FSD PHARMA INC (HUGE) Canada $0.024B 0.00
NF Energy Saving (BIMI) China $0.024B 0.00
Trinity Biotech (TRIB) Ireland $0.023B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.010B 0.00
Akers Biosciences Inc (AKER) United States $0.005B 0.00
Capricor Therapeutics (CAPR) United States $0.004B 0.00
Senestech (SNES) United States $0.004B 0.00
NeuroMetrix (NURO) United States $0.002B 0.00